DONATE Main navigation News Press Releases of The Lundquist Institute (formerly LA BioMed) RESEARCHERS Lundquist Institute Investigators Find That Early Administration of Convalescent Plasma Does Not Prevent COVID-19 Disease Progression Wednesday, August 18, 2021 Convalescent plasma from blood donors who have recovered from COVID-19 does not prevent disease in acutely ill, high-risk patients with COVID-19. Investigator(s): Investigator(s): Kabir Yadav, MDCM, MS, MSHS, FACEP Research Theme(s): Health Services and Outcomes Research LOS ANGELES — The Lundquist Institute announced that, in a new study published today in The New England Journal of Medicine, its Investigators and research colleagues at other institutions have found that passive immunization by infusion of COVID-19 convalescent plasma is not a viable strategy to reduce the severity of illness. Plasma from recovered patients who have already developed antibodies to SARS-CoV-2 is often the most readily available source of antibodies early in epidemics or emerging infections. Read more Lundquist Institute Investigators Contribute to Global Study Expanding Genomic Research Into Different Ancestries Monday, May 31, 2021 Paper in Nature Genetics: Genome-wide Meta-Analysis Shows That Research into Different Ancestries Leads to Better Results and Better Care Investigator(s): Investigator(s): Jerome I Rotter, MD Research Theme(s): Translational Genomics LOS ANGELES — Today The Lundquist Institute announced that its investigators contributed data from several studies, including data on Hispanics, African-Americans and East Asians, to the international MAGIC collaboration, composed of more than 400 global academics, who conducted a genome-wide association meta-analysis led by the University of Exeter. Now published in Nature Genetics, their findings demonstrate that expanding research into different ancestries yields more and better results, as well as ultimately benefitting global patient care. Read more Lundquist Institute Investigator Wei Yan, MD, PhD, Solves Longstanding Fallopian Tube Transport Debate Monday, May 24, 2021 Yan Group’s Research Shows That Motile Cilia Are Key to Oocyte Pickup in the Fallopian Tube Investigator(s): Investigator(s): Wei Yan, MD, PhD Research Theme(s): Metabolic Diseases, Translational Genomics Unlike the normal Fallopian tube (left), the "cilia-less" Fallopian tube fails to pick up ovulated eggs, leading to female infertility (right). Art by Tingting Xie. LOS ANGELES — Today, The Lundquist Institute announced that Wei Yan, MD, PhD, and his research group have solved a longstanding mystery and scientific debate about the mechanism underlying the gamete and embryo transport within the Fallopian tube. Using a mouse model where the animals lacked motile cilia in the oviduct, Dr. Read more Lundquist Institute Investigator Ashraf Ibrahim, PhD, Leads Life-Saving Research on Mucormycosis, the Deadly “Black Fungus” Thursday, May 13, 2021 Dr. Ibrahim’s start-up Vitalex Biosciences is manufacturing humanized monoclonal antibodies that would stem the spread of this fatal disease Investigator(s): Investigator(s): Ashraf Ibrahim, PhD Research Theme(s): Infection and Immunity LOS ANGELES — The Lundquist Institute today announced that one of its spinoff start-up companies, Vitalex Biosciences, founded by researcher Dr. Ashraf Ibrahim, is producing an antibody that stems the spread of mucormycosis, a deadly fungal infection with an overall mortality rate of 50% and higher. Mucormycosis is an emerging infection caused by exposure to mucor, a mold commonly found in soil, plants, manure, and decaying fruits and vegetables. Read more The Lundquist Institute Spearheads Life-Saving COVID-19 Clinical Research Trials in Rapid Response to the Pandemic Tuesday, April 27, 2021 COVID Research Supports The Institute’s Core Mission to Save Lives and Empower Healthcare Equity Investigator(s): Investigator(s): Eric Daar, MD, Loren Miller, MD, MPH, Michael Yeaman, PhD Research Theme(s): Infection and Immunity LOS ANGELES, CA — April 27, 2021 — Investigators at The Lundquist Institute at Harbor-UCLA Medical Center, a leading clinical research center on life-saving vaccines and treatments, have been among the first and foremost to respond against COVID-19. Since March 2020, The Lundquist Institute has led or participated in eight COVID-19 clinical studies and the results of this research have changed the world. This timely and vigorous response was due to the number of early cases and extreme COVID-19 infection surges in south-central Los Angeles. Read more The Lundquist Institute Spearheads Life-Saving COVID-19 Clinical Research Trials in Rapid Response to the Pandemic Tuesday, April 27, 2021 COVID Research Supports The Institute’s Core Mission to Save Lives and Empower Healthcare Equity Investigator(s): Investigator(s): Eric Daar, MD, Loren Miller, MD, MPH, Michael Yeaman, PhD Research Theme(s): Infection and Immunity LOS ANGELES, CA — April 27, 2021 — Investigators at The Lundquist Institute at Harbor-UCLA Medical Center, a leading clinical research center on life-saving vaccines and treatments, have been among the first and foremost to respond against COVID-19. Since March 2020, The Lundquist Institute has led or participated in eight COVID-19 clinical studies and the results of this research have changed the world. This timely and vigorous response was due to the number of early cases and extreme COVID-19 infection surges in south-central Los Angeles. Read more The Lundquist Institute Spearheads Life-Saving COVID-19 Clinical Research Trials in Rapid Response to the Pandemic Tuesday, April 27, 2021 COVID Research Supports The Institute’s Core Mission to Save Lives and Empower Healthcare Equity Investigator(s): Investigator(s): Eric Daar, MD, Loren Miller, MD, MPH, Michael Yeaman, PhD Research Theme(s): Infection and Immunity LOS ANGELES, CA — April 27, 2021 — Investigators at The Lundquist Institute at Harbor-UCLA Medical Center, a leading clinical research center on life-saving vaccines and treatments, have been among the first and foremost to respond against COVID-19. Since March 2020, The Lundquist Institute has led or participated in eight COVID-19 clinical studies and the results of this research have changed the world. This timely and vigorous response was due to the number of early cases and extreme COVID-19 infection surges in south-central Los Angeles. Read more Lundquist Institute Investigator Matt Budoff, Md, Presents Further Analyses Showing Icosapent Ethyl Significantly Reduces Coronary Plaque Saturday, April 17, 2021 Matthew Budoff, MD, Will Present the Analyses at the European Society of Cardiology (ESC) Preventive Cardiology 2021 Investigator(s): Investigator(s): Matthew Budoff, MD Research Theme(s): Metabolic Diseases, Women's and Children's Health LOS ANGELES (April 17, 2021) — Today, The Lundquist Institute announced that Matthew Budoff, MD, Director of Cardiovascular CT at the Institute and Professor of Medicine at the David Geffen School of Medicine at UCLA, will present further analyses from the Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients with Elevated Triglycerides on Statin Therapy: EVAPORATE Trial as Late- Breaking Science at European Society of Cardiology (ESC) Preventive Cardiology 2021, the Annual Congress of the European Association of Preventive Cardiology. Read more The Lundquist Institute Investigator Dong Chang’s Study on Nonbeneficial ICU Treatment Published in JAMA Internal Medicine Tuesday, April 13, 2021 For Critically Ill Patients with Advanced Medical Illnesses and Poor Prognoses, Overuse of Invasive ICU Treatment May Prolong Suffering Investigator(s): Investigator(s): Dong Chang, MD Research Theme(s): Health Services and Outcomes Research LOS ANGELES (April 13, 2021) — The Lundquist Institute (TLI) Investigator Dong W. Chang, MD, and his colleagues’ study on critically ill patients and ICU treatments was published in JAMA Internal Medicine. The study – “Evaluation of Time-Limited Trials Among Critically Ill Patients with Advanced Medical Illnesses and Reduction of Nonbeneficial ICU Treatments” – found that training physicians to communicate with family members of critically ill patients using a structured approach, which promotes shared decision-making, improved the quality of family meetings. Read more The Lundquist Institute Out-Licenses Development of a Synthetic Lung Surfactant Formulation Monday, March 8, 2021 Bill & Melinda Gates Medical Research Institute To Develop Formulation -Agreement advances evolution of synthetic lung surfactants to treat respiratory distress Syndrome in premature infants in Low- and Middle-Income Countries- Investigator(s): Investigator(s): Frans Walther, MD, PhD, FAAP Research Theme(s): Respiratory Medicine and Exercise Physiology, Women's and Children's Health LOS ANGELES — The Lundquist Institute (TLI) and The Bill & Melinda Gates Medical Research Institute (Gates MRI) executed a license agreement for TLI intellectual property covering a synthetic lung surfactant formulation to be developed for respiratory distress syndrome (RDS) for premature infants in Low- and Middle-Income countries (LMIC). TLI already maintains patents on this invention in the United States, Canada and Europe. Read more Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Next page Next › Last page Last » News Archive 2021 Jan Feb Mar Apr May Aug Sep Nov 2020 Jan Feb Mar May Jun Jul Aug Sep Oct Nov Dec 2019 Feb Mar Apr May Jun Aug Sep Oct Nov Dec 2018 Feb May Jun Jul Aug Sep Oct Nov Dec 2017 Feb Mar May Jun Jul Aug Oct 2016 Jan Feb Mar Apr May Jun Aug Sep Oct Nov Dec 2015 Jan Feb Mar Apr May Aug Oct Dec 2014 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2013 Jan Feb Mar Apr May Jun Aug Sep Oct Nov Dec 2012 May Nov Dec News Sidebar DONATE TODAY MEDIA COVERAGE VIDEOS Quick Links Clinical Trials Innovation Licensing Internship Inquiry Contact Us Visit Our Campus Contribute Become a Friend Planned Giving Donate Now Employee Links Benefits Remote Access Working at The Lundquist Institute Careers DONATE TODAY Search Social Links